174 filings
Page 8 of 9
8-K
dmxb5
4 Sep 19
Other Events
8:00am
8-K
014qw66w8gb871o3r
12 Aug 19
Applied Therapeutics Reports Second Quarter 2019 Financial Results
7:16am
8-K
ndikz3sq8qt
8 Aug 19
Applied Therapeutics Reports AT-007 SAD Data from Healthy Volunteer Portion of Phase 1/2 ACTION-Galactosemia Study
7:00am
8-K
7f03r
6 Aug 19
Regulation FD Disclosure
8:10am
8-K
yf7r3x8kqrgwi
24 Jun 19
Applied Therapeutics Announces Initiation of Phase 1/2 Study of AT-007 In Galactosemia
7:09am
10-Q
cuvpipx83 eb5
21 Jun 19
Quarterly report
7:48am
8-K
qylbte8l
21 Jun 19
Applied Therapeutics Reports First Quarter 2019 Financial Results
7:34am
8-K
536t257bh1cm
7 Jun 19
AT-001, a novel, potent and selective aldose reductase inhibitor, is expected to start a pivotal study later this year
7:59am
8-K
jtt2ojx e18qdik8
6 Jun 19
Departure of Directors or Certain Officers
4:05pm
8-K
fa8sx78y7641i
28 May 19
Applied Therapeutics Announces Fda Orphan Drug Designation for AT-007 In Galactosemia
5:14pm
8-K
6g4sv
24 May 19
Other Events
4:24pm
S-8
z2b1r5t
20 May 19
Registration of securities for employees
5:19pm
8-K
vow2xy51dnt
16 May 19
Amendments to Articles of Incorporation or Bylaws
5:22pm
424B4
r7yd 0kmbmix
14 May 19
Prospectus supplement with pricing info
4:21pm
EFFECT
c433 25tc
14 May 19
Notice of effectiveness
12:15am
CERT
7zw4yjok3
7 May 19
Certification of approval for exchange listing
12:25pm
8-A12B
dipnyop
6 May 19
Registration of securities on exchange
4:14pm
CORRESP
tun3aybydf 05g
6 May 19
Correspondence with SEC
12:00am
CORRESP
rzcyi
6 May 19
Correspondence with SEC
12:00am